Advertisement
Research Article

An LRP5 Receptor with Internal Deletion in Hyperparathyroid Tumors with Implications for Deregulated WNT/β-Catenin Signaling

  • Peyman Björklund,

    Affiliation: Department of Surgical Sciences, Uppsala University, Endocrine Unit, Uppsala University Hospital, Uppsala, Sweden

    X
  • Göran Åkerström,

    Affiliation: Department of Surgical Sciences, Uppsala University, Endocrine Unit, Uppsala University Hospital, Uppsala, Sweden

    X
  • Gunnar Westin mail

    To whom correspondence should be addressed. E-mail: gunnar.westin@surgsci.uu.se

    Affiliation: Department of Surgical Sciences, Uppsala University, Endocrine Unit, Uppsala University Hospital, Uppsala, Sweden

    X
  • Published: November 27, 2007
  • DOI: 10.1371/journal.pmed.0040328

About the Authors

Peyman Björklund, Göran Åkerström, Gunnar Westin
Department of Surgical Sciences, Uppsala University, Endocrine Unit, Uppsala University Hospital, Uppsala, Sweden

Corresponding Author

Email: gunnar.westin@surgsci.uu.se

Competing Interests

The authors declare the following competing interest: A patent is filed (USA) for “LRP5 and LRP6 Receptors in Cancer Treatment,” number WO2005048913.

Author Contributions

GW designed the study. PB performed experiments and analyzed data. PB, GÅ, and GW interpreted the data. GÅ reviewed clinical data. PB, GÅ, and GW contributed to writing the paper.